Platelet count and sustained virological response in hepatitis C treatment

被引：0

作者：

Tatsuo Kanda ^{[1
]}

Keizo Kato ^{[2
]}

Akihito Tsubota ^{[3
]}

Nobuo Takada ^{[4
]}

Takayoshi Nishino ^{[5
]}

Shigeru Mikami ^{[6
]}

Tatsuo Miyamura ^{[1
]}

Daisuke Maruoka ^{[1
]}

Shuang Wu ^{[1
]}

Shingo Nakamoto ^{[1
]}

Makoto Arai ^{[1
]}

Keiichi Fujiwara ^{[1
]}

Fumio Imazeki ^{[1
]}

Osamu Yokosuka ^{[1
]}

机构：

[1] Department of Gastroenterology and Nephrology,Graduate School of Medicine,Chiba University,Chiba 260-8677,Japan

[2] Department of Gastroenterology,Narita Red Cross Hospital,Narita 286-8523,Japan 3. Institute of Clinical Medicine and Research,Jikei University School of Medicine,Kashiwa 277-8567,Japan

来源：

World Journal of Hepatology | 2013年 / 5卷 / 04期

关键词：

Anemia; Antiviral treatment; Chronic hepatitis C; Platelet count; Sustained virological response;

D O I：

暂无

中图分类号：

R512.63 [];

学科分类号：

100401 ;

摘要：

AIM:To examine the epidemiological data,hematological safety and treatment responses of peginterferonalpha 2a plus ribavirin therapy for hepatitis C.METHODS:Between March 2008 and February 2011,196 hepatitis C virus(HCV)genotype 1 infected Japanese(127 treatment-naive and 69 treatment-experienced patients)patients treated with peginterferonalpha 2a plus ribavirin were enrolled.We examined the epidemiological data and treatment responses were retrospectively analyzed in terms of hematological safety.HCV RNA was measured by the COBAS TaqMan HCV test.RESULTS:Overall sustained virological response(SVR)rates of treatment-naive and treatment-experienced patients were 56% and 39%,respectively.Multivariate logistic regression analysis showed that SVR was attained independently of early virological response in both treatment-naive and treatment-experienced patients.SVR rates did not differ between the pretreatment hemoglobin < 13 g/dL and ≥ 13 g/dL groups.However,in treatment-naive patients,the SVR rate of the pretreatment platelet count < 130000/μL group was significantly lower than that of the pretreatment platelet count ≥ 130000/μL group.CONCLUSION:Attention should be paid to potential thrombocytopenia in the treatment of chronic hepatitis C patients.

引用

页码：182 / 188

页数：7

共 15 条

[1] Response to peginterferon-alpha 2b and ribavirin in Japanese patients with chronic hepatitis C genotype 1 [J].

Miyauchi, Tomoo ;

Kanda, Tatsuo ;

Imazeki, Fumio ;

Mikata, Rintaro ;

Tawada, Akinobu ;

Arai, Makoto ;

Fujiwara, Keiichi ;

Nakamoto, Shingo ;

Wu, Shuang ;

Tanaka, Takeshi ;

Miyamura, Tatsuo ;

Kimura, Michio ;

Hirai, Yasuo ;

Takashi, Motohide ;

Mikami, Shigeru ;

Sugiura, Nobuyuki ;

Natsuki, Yutaka ;

Azemoto, Ryosaku ;

Suzuki, Noriaki ;

Yokosuka, Osamu .

HEPATOLOGY INTERNATIONAL, 2013, 7 (01) :144-152

[2] Association of ITPA gene variation and serum ribavirin concentration with a decline in blood cell concentrations during pegylated interferon-alpha plus ribavirin therapy for chronic hepatitis C [J].

Nakagawa, Mina ;

Sakamoto, Naoya ;

Watanabe, Takako ;

Nishimura-Sakurai, Yuki ;

Onozuka, Izumi ;

Azuma, Seishin ;

Kakinuma, Sei ;

Nitta, Sayuri ;

Kiyohashi, Kei ;

Kusano-Kitazume, Akiko ;

Murakawa, Miyako ;

Yoshino, Kohei ;

Itsui, Yasuhiro ;

Tanaka, Yasuhito ;

Mizokami, Masashi ;

Watanabe, Mamoru .

HEPATOLOGY INTERNATIONAL, 2013, 7 (01) :153-161

[3] Peripheral blood cytopaenia limiting initiation of treatment in chronic hepatitis C patients otherwise eligible for antiviral therapy [J].

Giannini, Edoardo G. ;

Marenco, Simona ;

Fazio, Valentina ;

Pieri, Giulia ;

Savarino, Vincenzo ;

Picciotto, Antonino .

LIVER INTERNATIONAL, 2012, 32 (07) :1113-1119

[4]

Boceprevir and telaprevir for the treatment of chronic hepatitis C genotype 1 infection: an indirect comparison meta-analysis[J] . Edward Mills,El Khoury,Jean Nachega,Thorlund,Eric Druyts,Curtis Cooper,O’Regan.Therapeutics and Clinical Risk Management . 2012 (defa)

[5] APASL consensus statements and management algorithms for hepatitis C virus infection [J].

Omata, Masao ;

Kanda, Tatsuo ;

Yu, Ming-Lung ;

Yokosuka, Osamu ;

Lim, Seng-Gee ;

Jafri, Wasim ;

Tateishi, Ryosuke ;

Hamid, Saeed S. ;

Chuang, Wan-Long ;

Chutaputti, Anuchit ;

Wei, Lai ;

Sollano, Jose ;

Sarin, Shiv Kumar ;

Kao, Jia-Horng ;

McCaughan, Geoffrey W. .

HEPATOLOGY INTERNATIONAL, 2012, 6 (02) :409-435

[6]

Simple assay based on restriction fragment length polymorphism associated with IL28B in chronic hepatitis C patients[J] . Shingo Nakamoto,Tatsuo Kanda,Fumio Imazeki,Shuang Wu,Makoto Arai,Keiichi Fujiwara,Osamu Yokosuka.Scandinavian Journal of Gastroenterology . 2011 (7-8)

[7] Quantification of hepatitis C virus in patients treated with peginterferon-alfa 2a plus ribavirin treatment by COBAS TaqMan HCV test [J].

Kanda, T. ;

Imazeki, F. ;

Yonemitsu, Y. ;

Mikami, S. ;

Takada, N. ;

Nishino, T. ;

Takashi, M. ;

Tsubota, A. ;

Kato, K. ;

Sugiura, N. ;

Tawada, A. ;

Wu, S. ;

Tanaka, T. ;

Nakamoto, S. ;

Mikata, R. ;

Tada, M. ;

Chiba, T. ;

Kurihara, T. ;

Arai, M. ;

Fujiwara, K. ;

Kanai, F. ;

Yokosuka, O. .

JOURNAL OF VIRAL HEPATITIS, 2011, 18 (07) :E292-E297

[8]

Medical resource utilisation and healthcare costs in patients with chronic hepatitis C viral infection and thrombocytopenia[J] . Fred Poordad,Dickens Theodore,Jane Sullivan,Kelly Grotzinger.Journal of Medical Economics . 2011 (2)

[9]

Telaprevir with peginterferon and ribavirin for treatment-naive patients chronically infected with HCV of genotype 1 in Japan[J] . Hiromitsu Kumada,Joji Toyota,Takeshi Okanoue,Kazuaki Chayama,Hirohito Tsubouchi,Norio Hayashi.Journal of Hepatology . 2011 (1)

[10] New antiviral therapies for chronic hepatitis C [J].

Kanda, Tatsuo ;

Imazeki, Fumio ;

Yokosuka, Osamu .

HEPATOLOGY INTERNATIONAL, 2010, 4 (03) :548-561

← 1 2 →